Lamivir HBV Tablet contains Lamivudine 100mg, an antiretroviral medication primarily used in the treatment of chronic hepatitis B virus (HBV) infection. Lamivudine is a nucleoside analogue reverse transcriptase inhibitor (NRTI) that works by inhibiting the reverse transcriptase enzyme, thereby preventing viral replication and reducing viral load in infected hepatocytes. This action helps to improve liver function and reduce the risk of developing liver cirrhosis or hepatocellular carcinoma associated with chronic HBV infection. Lamivir HBV is indicated for patients with active HBV infection exhibiting elevated serum aminotransferase levels and evidence of viral replication. The medication is generally well tolerated, with common adverse effects including headache, fatigue, and gastrointestinal disturbances such as nausea and abdominal discomfort. Resistance to lamivudine may develop with prolonged use; therefore, regular monitoring of viral load and liver function tests is recommended during therapy. Lamivir HBV should be used under medical supervision, especially in patients with pre-existing liver conditions or co-infections such as HIV. Dose adjustments may be necessary in patients with renal impairment. Adherence to prescribed dosing regimens is critical to prevent resistance and achieve optimal therapeutic outcomes in the management of chronic hepatitis B.